{"id":11904,"date":"2026-02-19T12:48:12","date_gmt":"2026-02-19T11:48:12","guid":{"rendered":"https:\/\/iph-multisite.berta-bewegt.ch\/?p=11904"},"modified":"2026-03-05T08:55:33","modified_gmt":"2026-03-05T07:55:33","slug":"communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee","status":"publish","type":"post","link":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/","title":{"rendered":"Communiqu\u00e9 de presse: R\u00e9vision de l\u2019OAMal: r\u00e9\u00e9valuation plut\u00f4t que mise en \u0153uvre pr\u00e9cipit\u00e9e"},"content":{"rendered":"\n<p><strong>Depuis l\u2019adoption du 2e volet de mesures visant \u00e0 freiner la hausse des co\u00fbts, les conditions cadres internationales se sont profond\u00e9ment modifi\u00e9es, en particulier du fait de la nouvelle politique de prix am\u00e9ricaine qui peut avoir un impact direct sur la disponibilit\u00e9 de m\u00e9dicaments innovants en Suisse. L\u2019acc\u00e8s aux nouveaux traitements est d\u00e8s \u00e0 pr\u00e9sent limit\u00e9, ce qui accro\u00eet le risque que des m\u00e9dicaments arrivent sur le march\u00e9 avec encore plus de retard, voire pas du tout. Dans ce contexte, nous estimons qu\u2019entamer d\u00e8s \u00e0 pr\u00e9sent la consultation sur la r\u00e9vision de l\u2019OAMal, sans tenir compte int\u00e9gralement de l\u2019 \u00e9valuation commune finale de la situation que le groupe de travail \u00abplace \u00e9conomique Life Science\u00bb \u00e9labore actuellement, n\u2019est ni utile du point de vue de la proc\u00e9dure, ni justifi\u00e9 sur le fond.<\/strong><\/p>\n\n\n\n<p>Au printemps 2025, le Parlement a adopt\u00e9 le 2e volet de mesures visant \u00e0 freiner la hausse des co\u00fbts (2e volet). Mais depuis, le contexte de mise en \u0153uvre des diff\u00e9rentes mesures s\u2019est profond\u00e9ment modifi\u00e9, en particulier pour les mod\u00e8les d\u2019impact budg\u00e9taire et l\u2019acc\u00e8s aux nouveaux m\u00e9dicaments d\u00e8s le jour de leur autorisation de mise sur le march\u00e9. Toutes l\u00e9gitimes les mesures de ma\u00eetrise des co\u00fbts soient-elles, il est particuli\u00e8rement important dans le contexte actuel qu\u2019elles soient proportionn\u00e9es et acceptables eu \u00e9gard \u00e0 l\u2019acc\u00e8s des patient-e-s. Dans le projet qu\u2019il veut mettre en consultation, le Conseil f\u00e9d\u00e9ral ne saisit pas la chance de tenir compte des nouvelles conditions g\u00e9opolitiques. Bien au contraire, le projet fait l\u2019impasse sur les \u00e9volutions r\u00e9centes, ce qui, dans le pire des cas, sera au d\u00e9triment des patient-e-s de Suisse. Il faut \u00e0 pr\u00e9sent travailler en commun \u00e0 formuler une ordonnance qui cr\u00e9e les meilleures conditions cadres possibles pour assurer \u00e0 la population de la Suisse un acc\u00e8s durable aux m\u00e9dicaments innovants et vitaux.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-la-nouvelle-politique-de-prix-americaine-accentue-le-probleme\">La nouvelle politique de prix am\u00e9ricaine accentue le probl\u00e8me<\/h2>\n\n\n\n<p>Par la clause de la nation la plus favoris\u00e9e (\u00abMost Favored Nation\u00bb), les \u00c9tats-Unis ont introduit un syst\u00e8me de prix de r\u00e9f\u00e9rence qui tient compte des prix nets de la Suisse en parit\u00e9 de pouvoir d\u2019achat. Pour les entreprises pharmaceutiques, cela cr\u00e9e un dilemme de taille: si elles introduisent rapidement les m\u00e9dicaments innovants dans un petit march\u00e9 aux prix d\u00e9j\u00e0 bas comme la Suisse, cela a un impact direct sur les prix qui seront pratiqu\u00e9s sur le principal march\u00e9, celui des \u00c9tats-Unis. \u00c0 la cl\u00e9, les patient-e-s de Suisse risquent de ne plus avoir acc\u00e8s aux nouveaux traitements innovants ou seulement avec beaucoup de retard.<\/p>\n\n\n\n<p><strong>Ren\u00e9 Buholzer, directeur d\u2019Interpharma, d\u00e9clare:<\/strong><\/p>\n\n\n\n            <section class=\"highlightquote-block block-margins block-paddings-v2 scrollMagic-block visibleInBackend\" data-uid=\"69f4a11d282b9\">\n            <div class=\"block-bg bg-primary-10\"><\/div>\n\n            <div class=\"highlightquote-block-inner-container\">\n                <p class=\"quote mb-0\">\u00abDans le contexte des modifications de la situation internationale et des probl\u00e8mes d\u2019approvisionnement actuels, nous rejetons une r\u00e9vision de l\u2019OAMal qui ne tient pas compte des nouvelles conditions cadres. Il faut \u00e0 pr\u00e9sent r\u00e9\u00e9valuer soigneusement la situation, ce \u00e0 quoi travaille actuellement le groupe de travail \u2018place \u00e9conomique Life Science\u2019. Nous nous opposons \u00e0 une mise en \u0153uvre pr\u00e9cipit\u00e9e qui d\u00e9grade encore davantage l\u2019acc\u00e8s des patient-e-s.\u00bb<\/p>\n            <\/div>\n        <\/section>\n    \n\n\n\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-acces-aux-innovations-deja-limite-actuellement\">Acc\u00e8s aux innovations d\u00e9j\u00e0 limit\u00e9 actuellement<\/h2>\n\n\n\n<p>Ind\u00e9pendamment des modifications qui se produisent aux \u00c9tats-Unis, l\u2019acc\u00e8s aux m\u00e9dicaments innovants s\u2019est d\u00e9j\u00e0 d\u00e9grad\u00e9 progressivement en Suisse ces derni\u00e8res ann\u00e9es. Les nouveaux traitements arrivent aux patient-e-s avec de plus en plus de retard, voire plus du tout. En 2024, 47% seulement des m\u00e9dicaments innovants nouvellement autoris\u00e9s par l\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA) \u00e9taient enti\u00e8rement disponibles en Suisse.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-contradiction-avec-le-renforcement-de-la-place-des-sciences-de-la-vie\">Contradiction avec le renforcement de la place des sciences de la vie<\/h2>\n\n\n\n<p>Au d\u00e9but de l\u2019ann\u00e9e, le groupe de travail \u00abplace \u00e9conomique Life Science\u00bb, institu\u00e9 par le Conseil f\u00e9d\u00e9ral, s\u2019est mis au travail. Son but est d\u2019am\u00e9liorer durablement les conditions cadres pour la recherche, le d\u00e9veloppement et la production en Suisse. Connaissant le travail intensif men\u00e9 par le groupe de travail, Interpharma demande que les r\u00e9sultats de cet organe soient pris en compte dans l\u2019\u00e9valuation de la consultation. C\u2019est la seule mani\u00e8re de pouvoir atteindre les meilleurs r\u00e9sultats possibles pour les patient-e-s, la place \u00e9conomique et l\u2019industrie.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Depuis l\u2019adoption du 2e volet de mesures visant \u00e0 freiner la hausse des co\u00fbts, les conditions cadres internationales se sont profond\u00e9ment modifi\u00e9es, en particulier du fait de la nouvelle politique de prix am\u00e9ricaine qui peut avoir un impact direct sur la disponibilit\u00e9 de m\u00e9dicaments innovants en Suisse. L\u2019acc\u00e8s aux nouveaux traitements est d\u00e8s \u00e0 pr\u00e9sent [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1680,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[122,131],"class_list":["post-11904","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","tag-communique-de-presse","tag-politique"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Communiqu\u00e9 de presse: R\u00e9vision de l\u2019OAMal: r\u00e9\u00e9valuation plut\u00f4t que mise en \u0153uvre pr\u00e9cipit\u00e9e - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Communiqu\u00e9 de presse: R\u00e9vision de l\u2019OAMal: r\u00e9\u00e9valuation plut\u00f4t que mise en \u0153uvre pr\u00e9cipit\u00e9e\" \/>\n<meta property=\"og:description\" content=\"Depuis l\u2019adoption du 2e volet de mesures visant \u00e0 freiner la hausse des co\u00fbts, les conditions cadres internationales se sont profond\u00e9ment modifi\u00e9es, en particulier du fait de la nouvelle politique de prix am\u00e9ricaine qui peut avoir un impact direct sur la disponibilit\u00e9 de m\u00e9dicaments innovants en Suisse. L\u2019acc\u00e8s aux nouveaux traitements est d\u00e8s \u00e0 pr\u00e9sent [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-19T11:48:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-05T07:55:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/05\/Bundeshaus-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"berta_admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"berta_admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/\"},\"author\":{\"name\":\"berta_admin\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\"},\"headline\":\"Communiqu\u00e9 de presse: R\u00e9vision de l\u2019OAMal: r\u00e9\u00e9valuation plut\u00f4t que mise en \u0153uvre pr\u00e9cipit\u00e9e\",\"datePublished\":\"2026-02-19T11:48:12+00:00\",\"dateModified\":\"2026-03-05T07:55:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/\"},\"wordCount\":682,\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/05\/Bundeshaus-scaled.jpg\",\"keywords\":[\"Communiqu\u00e9 de presse\",\"Politique\"],\"inLanguage\":\"fr-FR\",\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/\",\"url\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/\",\"name\":\"Communiqu\u00e9 de presse: R\u00e9vision de l\u2019OAMal: r\u00e9\u00e9valuation plut\u00f4t que mise en \u0153uvre pr\u00e9cipit\u00e9e - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/05\/Bundeshaus-scaled.jpg\",\"datePublished\":\"2026-02-19T11:48:12+00:00\",\"dateModified\":\"2026-03-05T07:55:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/#primaryimage\",\"url\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/05\/Bundeshaus-scaled.jpg\",\"contentUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/05\/Bundeshaus-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Communiqu\u00e9 de presse: R\u00e9vision de l\u2019OAMal: r\u00e9\u00e9valuation plut\u00f4t que mise en \u0153uvre pr\u00e9cipit\u00e9e\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\",\"name\":\"berta_admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"caption\":\"berta_admin\"},\"sameAs\":[\"https:\/\/interpharma.ch\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Communiqu\u00e9 de presse: R\u00e9vision de l\u2019OAMal: r\u00e9\u00e9valuation plut\u00f4t que mise en \u0153uvre pr\u00e9cipit\u00e9e - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/","og_locale":"fr_FR","og_type":"article","og_title":"Communiqu\u00e9 de presse: R\u00e9vision de l\u2019OAMal: r\u00e9\u00e9valuation plut\u00f4t que mise en \u0153uvre pr\u00e9cipit\u00e9e","og_description":"Depuis l\u2019adoption du 2e volet de mesures visant \u00e0 freiner la hausse des co\u00fbts, les conditions cadres internationales se sont profond\u00e9ment modifi\u00e9es, en particulier du fait de la nouvelle politique de prix am\u00e9ricaine qui peut avoir un impact direct sur la disponibilit\u00e9 de m\u00e9dicaments innovants en Suisse. L\u2019acc\u00e8s aux nouveaux traitements est d\u00e8s \u00e0 pr\u00e9sent [&hellip;]","og_url":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/","og_site_name":"Interpharma","article_published_time":"2026-02-19T11:48:12+00:00","article_modified_time":"2026-03-05T07:55:33+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/05\/Bundeshaus-scaled.jpg","type":"image\/jpeg"}],"author":"berta_admin","twitter_card":"summary_large_image","twitter_creator":"@interpharma_ch","twitter_site":"@interpharma_ch","twitter_misc":{"\u00c9crit par":"berta_admin","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/#article","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/"},"author":{"name":"berta_admin","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818"},"headline":"Communiqu\u00e9 de presse: R\u00e9vision de l\u2019OAMal: r\u00e9\u00e9valuation plut\u00f4t que mise en \u0153uvre pr\u00e9cipit\u00e9e","datePublished":"2026-02-19T11:48:12+00:00","dateModified":"2026-03-05T07:55:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/"},"wordCount":682,"publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/05\/Bundeshaus-scaled.jpg","keywords":["Communiqu\u00e9 de presse","Politique"],"inLanguage":"fr-FR","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.interpharma.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/","url":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/","name":"Communiqu\u00e9 de presse: R\u00e9vision de l\u2019OAMal: r\u00e9\u00e9valuation plut\u00f4t que mise en \u0153uvre pr\u00e9cipit\u00e9e - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/#primaryimage"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/05\/Bundeshaus-scaled.jpg","datePublished":"2026-02-19T11:48:12+00:00","dateModified":"2026-03-05T07:55:33+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/#primaryimage","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/05\/Bundeshaus-scaled.jpg","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2020\/05\/Bundeshaus-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-reevaluation-plutot-que-mise-en-oeuvre-precipitee\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Communiqu\u00e9 de presse: R\u00e9vision de l\u2019OAMal: r\u00e9\u00e9valuation plut\u00f4t que mise en \u0153uvre pr\u00e9cipit\u00e9e"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]},{"@type":"Person","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818","name":"berta_admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","caption":"berta_admin"},"sameAs":["https:\/\/interpharma.ch"]}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/11904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=11904"}],"version-history":[{"count":3,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/11904\/revisions"}],"predecessor-version":[{"id":14670,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/11904\/revisions\/14670"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media\/1680"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=11904"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/tags?post=11904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}